CROIXSSANCE PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CROIXSSANCE PHARMA
Largest movements
- Receivables within one year -€12,564
down €12,564 (-68.7%), from €18,284 to €5,720
of which Trade receivables: -€11,143
- Cash -€7,977
down €7,977 (-84.3%), from €9,462 to €1,485
mainly Other debts (-€22,102) and Trade debts (-€3,244)
- Tangible fixed assets -€840
down €840 (-27.0%), from €3,109 to €2,269
of which Plant, machinery and equipment: -€1,229
- Other debts -€22,102
down €22,102 (-54.2%), from €40,794 to €18,692
- Trade debts -€3,244
down €3,244 (-57.0%), from €5,688 to €2,444
- Tax, wage and social debts +€2,105
up €2,105 (+169%), from €1,249 to €3,353
- Profit (loss) carried forward +€1,861
up €1,861 (+5.2%), from -€35,476 to -€33,615
- Gross operating margin +€3,482
up €3,482 (+151%), from €2,300 to €5,783
- Financial charges -€192
down €192 (-11.6%), from €1,653 to €1,461
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €30,855 | €9,474 | -€21,381 | -69.3% |
| Fixed assets | 21/28 | €3,109 | €2,269 | -€840 | -27.0% |
| Tangible fixed assets | 22/27 | €3,109 | €2,269 | -€840 | -27.0% |
| Plant, machinery and equipment | 23 | €2,548 | €1,319 | -€1,229 | -48.2% |
| Furniture and vehicles | 24 | €560 | €950 | +€390 | +69.6% |
| Current assets | 29/58 | €27,746 | €7,205 | -€20,541 | -74.0% |
| Amounts receivable within one year | 40/41 | €18,284 | €5,720 | -€12,564 | -68.7% |
| Trade receivables | 40 | €15,962 | €4,818 | -€11,143 | -69.8% |
| Other amounts receivable | 41 | €2,322 | €902 | -€1,421 | -61.2% |
| Cash at bank and in hand | 54/58 | €9,462 | €1,485 | -€7,977 | -84.3% |
| Total equity and liabilities | 10/49 | €30,855 | €9,474 | -€21,381 | -69.3% |
| Equity | 10/15 | -€16,876 | -€15,015 | +€1,861 | +11.0% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€35,476 | -€33,615 | +€1,861 | +5.2% |
| Amounts payable | 17/49 | €47,731 | €24,489 | -€23,242 | -48.7% |
| Amounts payable within one year | 42/48 | €47,731 | €24,489 | -€23,242 | -48.7% |
| Trade debts | 44 | €5,688 | €2,444 | -€3,244 | -57.0% |
| Suppliers | 440/4 | €5,688 | €2,444 | -€3,244 | -57.0% |
| Taxes, remuneration and social security | 45 | €1,249 | €3,353 | +€2,105 | +169% |
| Taxes | 450/3 | €1,249 | €3,353 | +€2,105 | +169% |
| Other amounts payable | 47/48 | €40,794 | €18,692 | -€22,102 | -54.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,068 | €2,083 | +€15 | +0.7% |
| Gross operating margin | 9900 | €2,300 | €5,783 | +€3,482 | +151% |
| Operating profit (loss) | 9901 | €232 | €3,700 | +€3,468 | +1,492% |
| Financial charges | 65/66B | €1,653 | €1,461 | -€192 | -11.6% |
| Recurring financial charges | 65 | €1,653 | €1,461 | -€192 | -11.6% |
| Profit (loss) for the period before taxes | 9903 | -€1,421 | €2,239 | +€3,660 | |
| Income taxes | 67/77 | €380 | €378 | -€2 | -0.5% |
| Profit (loss) for the period | 9904 | -€1,801 | €1,861 | +€3,662 | |
| Profit (loss) for the period to be appropriated | 9905 | -€1,801 | €1,861 | +€3,662 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 18 October 2026 via checked.be.